Stay updated on Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page
- Check4 days agoChange DetectedThe web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.SummaryDifference0.2%
- Check11 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.1%
- Check18 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference1.0%
- Check25 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed. Additionally, a significant piece of information regarding the modernization of ClinicalTrials.gov data ingest in July 2025 has been deleted.SummaryDifference1%
- Check33 days agoNo Change Detected
- Check40 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.9%
- Check47 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HR+ Inflammatory Breast Cancer Clinical Trial page.